FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293568020> ?p ?o ?g. }

• W4293568020 endingPage "118" @default.
• W4293568020 startingPage "110" @default.
• W4293568020 abstract "The French health authorities are considering expanding the current selective hepatitis E virus (HEV)-RNA testing procedure to include all donations in order to further reduce transfusion-transmitted HEV infection. Data obtained from blood donors (BDs) tested for HEV-RNA between 2015 and 2021 were used to assess the most efficient nucleic acid testing (NAT) strategy.Viral loads (VLs) and the plasma volume of blood components, as well as an HEV-RNA dose of 3.85 log IU as the infectious threshold and an assay with a 95% limit of detection (LOD) at 17 IU/mL, were used to assess the proportion of: (i) HEV-RNA-positive BDs that would remain undetected; and (ii) blood components associated with these undetected BDs with an HEV-RNA dose >3.85 log IU, considering 4 NAT options (Individual testing [ID], MP-6, MP-12, and MP-24).Of the 510,118 BDs collected during the study period, 510 (0.10%) were HEV-RNA-positive. Based on measurable VLs available in 388 cases, 1%, 15.2%, 21.8%, and 32.6% of BDs would theoretically pass undetected due to a VL below the LOD of ID, MP-6, MP-12, and MP-24 testing, respectively. All BDs associated with a potentially infectious blood component would be detected with ID-NAT while 13% of them would be undetected with MP-6, 19.6% with MP-12, and 30.4% with MP-24 depending on the plasma volume. No red blood cell (RBC) components with an HEV-RNA dose >3.85 log IU would enter the blood supply, regardless of the NAT strategy used.A highly sensitive ID-NAT would ensure maximum safety. However, an MP-based strategy can be considered given that: (i) the risk of transmission is closely related to the plasma volume of blood components; (ii) RBC are the most commonly transfused components and have a low plasma content; and (iii) HEV-RNA doses transmitting infection exceed 4 log IU. To minimise the potential risk associated with apheresis platelet components and fresh frozen plasma, less than 12 donations should be pooled using an NAT assay with a LOD of approximately 20 IU/mL." @default.
• W4293568020 created "2022-08-30" @default.
• W4293568020 creator A5005198529 @default.
• W4293568020 creator A5014799623 @default.
• W4293568020 creator A5025248485 @default.
• W4293568020 creator A5026746168 @default.
• W4293568020 creator A5030246196 @default.
• W4293568020 creator A5039724558 @default.
• W4293568020 creator A5041649113 @default.
• W4293568020 creator A5056692731 @default.
• W4293568020 creator A5072532132 @default.
• W4293568020 creator A5078450368 @default.
• W4293568020 creator A5080763997 @default.
• W4293568020 creator A5083271501 @default.
• W4293568020 date "2023-03-01" @default.
• W4293568020 modified "2023-10-15" @default.
• W4293568020 title "Seven years (2015-2021) of blood donor screening for HEV-RNA in France: lessons and perspectives." @default.
• W4293568020 cites W1995178834 @default.
• W4293568020 cites W1995985197 @default.
• W4293568020 cites W2018642493 @default.
• W4293568020 cites W2026005382 @default.
• W4293568020 cites W2107016072 @default.
• W4293568020 cites W2144044710 @default.
• W4293568020 cites W2150602209 @default.
• W4293568020 cites W2160321243 @default.
• W4293568020 cites W2165008961 @default.
• W4293568020 cites W2165729807 @default.
• W4293568020 cites W2167036778 @default.
• W4293568020 cites W2398055824 @default.
• W4293568020 cites W2495200628 @default.
• W4293568020 cites W2584433886 @default.
• W4293568020 cites W2607889826 @default.
• W4293568020 cites W2611630037 @default.
• W4293568020 cites W2732176101 @default.
• W4293568020 cites W2750684049 @default.
• W4293568020 cites W2790597728 @default.
• W4293568020 cites W2808993200 @default.
• W4293568020 cites W2897102994 @default.
• W4293568020 cites W2921370618 @default.
• W4293568020 cites W2951446603 @default.
• W4293568020 cites W2964355895 @default.
• W4293568020 cites W3002527397 @default.
• W4293568020 cites W3088555059 @default.
• W4293568020 cites W3154818934 @default.
• W4293568020 cites W3198117620 @default.
• W4293568020 cites W3207812605 @default.
• W4293568020 cites W4200150690 @default.
• W4293568020 cites W4200607093 @default.
• W4293568020 doi "https://doi.org/10.2450/2022.0052-22" @default.
• W4293568020 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35969132" @default.
• W4293568020 hasPublicationYear "2023" @default.
• W4293568020 type Work @default.
• W4293568020 citedByCount "1" @default.
• W4293568020 countsByYear W42935680202023 @default.
• W4293568020 crossrefType "journal-article" @default.
• W4293568020 hasAuthorship W4293568020A5005198529 @default.
• W4293568020 hasAuthorship W4293568020A5014799623 @default.
• W4293568020 hasAuthorship W4293568020A5025248485 @default.
• W4293568020 hasAuthorship W4293568020A5026746168 @default.
• W4293568020 hasAuthorship W4293568020A5030246196 @default.
• W4293568020 hasAuthorship W4293568020A5039724558 @default.
• W4293568020 hasAuthorship W4293568020A5041649113 @default.
• W4293568020 hasAuthorship W4293568020A5056692731 @default.
• W4293568020 hasAuthorship W4293568020A5072532132 @default.
• W4293568020 hasAuthorship W4293568020A5078450368 @default.
• W4293568020 hasAuthorship W4293568020A5080763997 @default.
• W4293568020 hasAuthorship W4293568020A5083271501 @default.
• W4293568020 hasConcept C104317684 @default.
• W4293568020 hasConcept C126322002 @default.
• W4293568020 hasConcept C135763542 @default.
• W4293568020 hasConcept C159047783 @default.
• W4293568020 hasConcept C182516595 @default.
• W4293568020 hasConcept C203014093 @default.
• W4293568020 hasConcept C2779134260 @default.
• W4293568020 hasConcept C2780014101 @default.
• W4293568020 hasConcept C2780777367 @default.
• W4293568020 hasConcept C2781369635 @default.
• W4293568020 hasConcept C3008058167 @default.
• W4293568020 hasConcept C31258907 @default.
• W4293568020 hasConcept C41008148 @default.
• W4293568020 hasConcept C524204448 @default.
• W4293568020 hasConcept C55493867 @default.
• W4293568020 hasConcept C67705224 @default.
• W4293568020 hasConcept C71924100 @default.
• W4293568020 hasConcept C86803240 @default.
• W4293568020 hasConceptScore W4293568020C104317684 @default.
• W4293568020 hasConceptScore W4293568020C126322002 @default.
• W4293568020 hasConceptScore W4293568020C135763542 @default.
• W4293568020 hasConceptScore W4293568020C159047783 @default.
• W4293568020 hasConceptScore W4293568020C182516595 @default.
• W4293568020 hasConceptScore W4293568020C203014093 @default.
• W4293568020 hasConceptScore W4293568020C2779134260 @default.
• W4293568020 hasConceptScore W4293568020C2780014101 @default.
• W4293568020 hasConceptScore W4293568020C2780777367 @default.
• W4293568020 hasConceptScore W4293568020C2781369635 @default.
• W4293568020 hasConceptScore W4293568020C3008058167 @default.
• W4293568020 hasConceptScore W4293568020C31258907 @default.
• W4293568020 hasConceptScore W4293568020C41008148 @default.

• next